Jeffrey Girshman - Concepedia

Author

Jeffrey Girshman

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

Erin F Gillespie, J Girshman, J. Girshman, Jeffrey Girshman

106

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Brigham and Women's Hospital Research Institute Hospital 12 de Octubre University of Miami

About

Jeffrey Girshman is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	891
2	Engineering	2	2	324
3	Health Sciences	1	1	67
4	Biochemistry	1	1	312
5	Cell Biology	1	1	12

Jeffrey Girshman

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib Adam J. Schoenfeld, Kathryn C. Arbour, Hira Rizvi, Annals of Oncology Clinical ImmunologyAutoimmune DiseaseImmunologyImmune Checkpoint InhibitorAutoimmunity	2019	401
Membrane Stiffness and Channel Function Jens A. Lundbæk, P. Birn, Jeffrey Girshman, Biochemistry Membrane StructureProteinlipid InteractionShifts Channel InactivationEngineeringLipid Movement	1996	312
Regulation of Sodium Channel Function by Bilayer Elasticity Jens A. Lundbæk, P. Birn, Anker Jón Hansen, The Journal of General Physiology	2004	263
CT-Guided Percutaneous Catheter Drainage of Acute Necrotizing Pancreatitis: Clinical Experience and Observations in Patients with Sterile and Infected Necrosis Koenraad J. Mortelé, Jeffrey Girshman, Dênis Szejnfeld, American Journal of Roentgenology	2008	126
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non–Small-Cell Lung Cancer Natalie I. Vokes, David Liu, Biagio Ricciuti, JCO Precision Oncology	2019	119
<i>MET</i> Exon 14–altered Lung Cancers and MET Inhibitor Resistance Robin Guo, Michael Offin, A. Rose Brannon, Clinical Cancer Research	2020	78
Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression ― Interim Analysis of the First Randomized Study of Stereotactic Body Radiotherapy in Patients With Oligoprogressive Metastatic Cancers of the Lung and Breast C. Jillian Tsai, Jie Yang, David Guttmann, International Journal of Radiation OncologyBiologyPhysics Radiation MedicineCancer TherapeuticsRadiation TherapyOligoprogressive Metastatic CancersTreatment Verification	2021	67
Active Surveillance of Papillary Thyroid Cancer: Frequency and Time Course of the Six Most Common Tumor Volume Kinetic Patterns R. Michael Tuttle, James A. Fagin, Gerald Minkowitz, Thyroid	2022	57
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics Laura Mezquita, Isabel R. Preeshagul, Édouard Auclin, European Journal of Cancer Advanced NsclcEarly DynamicsDisease ProgressionImmunodeficienciesImmunotherapy Outcomes	2021	56
Urethral Diverticula in Women: Discrepancies Between Magnetic Resonance Imaging and Surgical Findings Doreen E. Chung, Rajveer S. Purohit, Jeffrey Girshman, The Journal of Urology	2010	55

Page 1